|
Volumn 51, Issue 3, 1992, Pages 249-259
|
Human pharmacokinetics of N‐l‐leucyl‐doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities
a,b,c,d,e a,b,c,d,e a,b,c,d,e a,b,c,d,e a,b,c,d,e a,b,c,d,e a,b,c,d,e a,b,c,d,e a,b,c,d,e a,b,c,d,e a,b,c,d,e
c
Medgenix Group
*
(Belgium)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTHRACYCLINE DERIVATIVE;
DOXORUBICIN;
DOXORUBICINOL;
DRUG METABOLITE;
LEURUBICIN;
N LEUCYLDOXORUBICINOL;
UNCLASSIFIED DRUG;
ADVANCED CANCER;
AREA UNDER THE CURVE;
ARTICLE;
CLINICAL ARTICLE;
CONTROLLED STUDY;
DRUG BLOOD LEVEL;
DRUG METABOLISM;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
LEUKOPENIA;
PHARMACOKINETICS;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
STOMATITIS;
THROMBOCYTOPENIA;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOXORUBICIN;
DRUG EVALUATION;
HUMAN;
LEUKOCYTE COUNT;
PLATELET COUNT;
REGRESSION ANALYSIS;
STOMATITIS;
|
EID: 0026589540
PISSN: 00099236
EISSN: 15326535
Source Type: Journal
DOI: 10.1038/clpt.1992.19 Document Type: Article |
Times cited : (17)
|
References (0)
|